PHP
ADPT icon

Parkman Healthcare Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Parkman Healthcare Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.66M Buy
551,815
+150,085
+37% +$2.39M 0.79% 46
2025
Q4 		$6.52M Buy
+401,730
New +$6.56M 0.62% 51

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parkman Healthcare Partners's ADPT Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Adaptive Biotechnologies (ADPT) stake by 37% in Q1 2026, buying an estimated $2.39M and bringing the position to 551,815 shares worth $7.66M. The position accounts for 0.79% of the portfolio, ranked #46.

Parkman Healthcare Partners first reported a position in ADPT in Q4 2025 and has held it in 2 quarters since. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Parkman Healthcare Partners held 551,815 shares of Adaptive Biotechnologies worth $7.66M as of Q1 2026.
  • Parkman Healthcare Partners bought 150,085 Adaptive Biotechnologies shares in Q1 2026, an estimated $2.39M.
  • Adaptive Biotechnologies made up 0.79% of Parkman Healthcare Partners's portfolio in Q1 2026, its #46 holding.
  • Parkman Healthcare Partners first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 2 quarters since.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.